In an extravagant attempt to tackle the UK’s unemployment crisis, the government has decided that weight loss shots might just be the magic bullet. Prime Minister Keir Starmer and Health Secretary Wes Streeting are pinning their hopes on drugs like Mounjaro and Ozempic, suggesting these could be the key to getting people back to work. This innovative approach, backed by a substantial investment from pharmaceutical giant Eli Lilly, will be tested in a five-year study in Greater Manchester.
The study, part of the Surmount-Real UK trial, aims to evaluate the long-term effects of tirzepatide (the active ingredient in Mounjaro) on about 3,000 participants. The rationale behind this initiative is rooted in the alarming prevalence of obesity in the UK: more than a quarter of adults are classified as obese and nearly a quarter as overweight. These conditions are a significant drain on the NHS, costing an estimated £11 billion annually, according to Health Secretary Wes Streeting.
While the UK’s unemployment rate stands at 4%, there’s a lingering concern about economic inactivity, with around 9.26 million people between 16 and 64 years old not in employment or actively seeking work. Obesity and related health issues like diabetes are suspected to be contributing factors, although the relationship is complex and requires more research. Experts argue that while obesity is more common among the unemployed, the link between these health conditions and joblessness is far from clear-cut.
The idea that weight loss medications can indirectly boost employment by improving health and well-being sounds promising, but it remains a theory without conclusive evidence. These medications, which work by mimicking the hormone glucagon-like peptide-1 (GLP-1) to suppress appetite, have shown impressive weight loss results in clinical trials. However, the weight loss is not sustainable without continued use of the medications, as studies indicate that the lost weight will return within a year of stopping.
The potential side effects of these medications are a laundry list of unpleasantness, including nausea, diarrhoea, decreased appetite, vomiting, constipation, indigestion, and stomach pain. More serious risks include pancreatic inflammation, low blood sugar, allergic reactions, severe stomach problems, changes in vision, and gallbladder issues. Despite these risks, the UK government is hopeful that this trial will provide the data needed to support their unconventional strategy.
In the midst of this, it’s worth noting that the broader economic landscape is not particularly favourable. A recent report by Korn Ferry highlighted that AI and economic uncertainty are creating a “perfect storm” that’s reducing job availability. Companies like Cisco, Microsoft, and Intuit are cutting jobs, citing automation as a reason, which doesn’t exactly create a welcoming job market for those hoping to return to work, slimmed down or not.
So, as the UK embarks on this experiment, it’s hard not to wonder if weight loss shots are just a Band-Aid on a much deeper wound. Will slimmer job seekers really face less bias in interviews or find it easier to handle strenuous workloads? Only time, and a lot of data, will tell. But for now, it seems the UK is betting on a rather slim chance that weight loss medications will be the solution to its unemployment woes.
